Navigation Links
IntegriChain Launches DNA: Dynamic NextGen Analytics(TM) Platform
Date:2/16/2010

PRINCETON, N.J., Feb. 16 /PRNewswire/ -- IntegriChain, Inc., a commercial insight provider supporting the pharmaceutical industry, announces the launch of its new DNA: Dynamic NextGen Analytics™ (DNA) platform. This powerful new analytic platform helps pharmaceutical manufacturers unlock the value of Direct Data through data integration, enrichment and guided analytics. Direct Data includes those data assets typically provided to the manufacturer as a function of other agreements such as fee for service, rebates, coupon programs and chargebacks.

"The pharmaceutical industry is swamped with data, both syndicated and direct. Yet answers to fundamental questions are still difficult to find. Newly emerging data sets including syndicated retail data are compounding the problem," states Kevin Leininger, IntegriChain's CEO. "Poor data quality, high cost, high latency and the historical ad-hoc nature of projects in our industry have created pressure for pharmaceutical executives. Pre-existing solutions have simply been inadequate to allow manufacturers to build a sufficient value proposition around what should be a widely leveraged, shared data asset."

IntegriChain's DNA platform has been built upon a SaaS architecture and scales to support dynamic analysis of a billion+ transaction volumes with minimal latency. The robust architecture, data warehousing and analytic capabilities of DNA can be accessed via a zero-footprint web interface, further reducing the total cost of ownership for IntegriChain's customers.

As part of the DNA: NextGen Analytics platform, IntegriChain is providing customers with a series of advanced analytical modules — DNA: Channel™, DNA: Chargeback Validation ® and DNA: Measurement of Retail Inventory™ — to maximize the value of Direct Data within multiple functions of the commercial pharmaceutical organization, including Trade Operations, Finance, Managed Markets and Brand Marketing. Through DNA: Channel, IntegriChain now offers the opportunity for customers to directly connect with trading partners, providing near real-time, on-line access to all EDI data streams. All of the analytics within the platform leverage IntegriChain's Enriched Channel Sales™, the company's unparalleled channel data enrichment service that brings full transparency and strong business value to traditionally redacted and, therefore, unusable channel data. The DNA platform will allow IntegriChain to rapidly deploy additional analytic modules as the pharmaceutical industry continues to evolve.

"DNA is a low latency platform that uses a customer's own data to quickly and inexpensively answer a whole host of questions critical to the new commercial model emerging in pharma. DNA solves manufacturers' inherent data challenges," noted Leininger.

DNA: Dynamic NextGen Analytics from IntegriChain is available now and is currently in production at IntegriChain's industry-leading clients, spanning small, medium and top-tier pharmaceutical manufacturers. IntegriChain offers a rapid deployment program that can have most manufacturers fully implemented in less than 90 days.

IntegriChain embraces the concept of guided analytics — a combination of cutting-edge business intelligence technology, advanced visualization, statistical tools and subject matter expertise. DNA: Dynamic NextGen Analytics is the only single source solution for collection, enrichment, query and advanced analytics of all Direct Data, providing 100 percent visibility to commercial demand in a low-latency business insight platform.

About IntegriChain

IntegriChain enables manufacturers to improve sales performance and total pipeline measurement by maximizing visibility to the down-stream channel. IntegriChain's DNA: Dynamic NextGen Analytics are transforming the role of channel data within key pharmaceutical application areas including product launch, sales reporting, sales forecasting and demand analysis. IntegriChain is a privately held, venture-backed company headquartered in Princeton, New Jersey, and has been deployed across a growing number of pharmaceutical manufacturers including six of the top ten global leaders in the pharmaceutical industry.

SOURCE IntegriChain, Inc.

RELATED LINKS
http://www.integrichain.com

'/>"/>

SOURCE IntegriChain, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
2. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
3. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
4. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
7. Premier Micronutrient Launches Supplement for Hearing Health
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
10. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
11. PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):